TSPO and multiple system atrophy: As for other neurodegenerative conditions, TSPO PET has been successfully applied in synucleinopathies, such as in DLB, PD, and PD with dementia173–175; in FTD176; in atypical parkinsonisms such as multiple system atrophy (MSA), CBD, and PSP177–179; and in prion diseases, such as Creutzfeldt-Jakob disease180.